Immunophenotyping

Dacie and Lewis Practical Haematology

Volumn , Issue , 2006, Pages 335-355

  Matutes, Estella ^a   Morilla, Ricardo ^a   Catovsky, Daniel ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955739316     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-44-306660-4/50018-0     Document Type: Chapter

References (52)

1. Groeneveld K, Temarvelde JG, van den Beemd MWM, et al. Flow cytometry detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. BTS Technical Report. Leukemia 1996, 10:1383-1389.
2. Pizzolo G, Vincenzi C, Nadali G, et al. Detection of membrane and intracellular antigens by flow cytometry following ORTHO PermeaFix fixation. Leukemia 1995, 9:226-228.
3. Bikoue A, George F, Poncelet LW, et al. Quantitative analysis of leukocyte membrane antigen expression: normal adult values. Cytometry 1996, 26:137-147.
4. Poncelet P, George F, Papa S, et al. Quantitation of haemopoietic cell antigens in flow cytometry. European Journal of Histochemistry 1996, 40(suppl 1):15-32.
5. Erber WN, Mynheer LC, Mason DY APAAP labelling of blood and bone-marrow samples for phenotyping leukaemia. Lancet 1986, i:761-765.
6. Mason DY, Erber WN Immunocytochemical labeling of leukemia samples with monoclonal antibodies by the APAAP procedure. The leukemic cell 1991, 196. Churchill Livingstone, Edinburgh. D. Catovsky (Ed.).
7. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. Leukemia 1995, 9:1783-1786.
8. Bain BJ, Barnett D, Linch D, et al. Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. Clinical and Laboratory Haematology 2002, 24:1-13.
9. Janossy G, Coustan-Smith E, Campana D The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. Leukemia 1989, 3:170-181.
10. Buccheri V, Shetty V, Yoshida N, et al. The role of an anti-myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry. British Journal of Haematology 1992, 80:62-68.
11. Buccheri V, Milhaljevic B, Matutes E, et al. mb-1: a new marker for B-lineage lymphoblastic leukemia. Blood 1993, 82:853-857.
12. Tetteroo PAT, Lansdorp PM, Leeksma OC, et al. Monoclonal antibodies against human platelet glycoprotein IIIa. British Journal of Haematology 1983, 55:509-522.
13. O'Connor SJ, Forsyth PD, Dalal S, et al. The rapid diagnosis of acute promyelocytic leukaemia using PML (5E10) monoclonal antibody. British Journal of Haematology 1997, 99:597-604.
14. Falini B, Flenghi L, Lo Coco F, et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 1997, 90:4046-4053.
15. Behm FG, Smith FO, Raimondi SC, et al. Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1 identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL rearrangements. Blood 1996, 87:1134-1139.
16. Wutchter C, Schnittger S, Schoch C, et al. Detection of acute leukemia cells with 11q23 rearrangements by flow cytometry: sensitivity and specificity of monoclonal antibody 7.1. Blood 1998, 92(suppl 1):228a.
17. Smith FO, Rauch C, Williams DE, et al. The human homologue of rat NG2, a chondroitin sulfate proteoglycan is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor prognosis patients with abnormalities of chromosome band 11q23. Blood 1996, 87:1123-1133.
18. Mauvieux L, Delabesse E, Bourquelot P, et al. NG2 expression in MLL rearranged acute myeloid leukaemia is restricted to monoblastic cases. British Journal of Haematology 1999, 107:674-676.
19. Brunning RD, Borowitz M, Matutes E, et al. Precursor B lymphoblastic leukaemia/lymphoblastic lymphoma. World Health Organization classification of tumours: tumours of haemopoietic and lymphoid tissues 2001, 111-114. IARC Press, Lyon. E.S. Jaffe, N.L. Harris, H. Stein (Eds.).
20. Bene MC, Bernier M, Casasnovas RO, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. Blood 1998, 92:596-599.
21. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Annals of Internal Medicine 1985, 103:620-625.
22. Matutes E, de Oliveria MP, Foroni L, et al. The role of ultrastructural cytochemistry and monoclonal antibodies in clarifying the nature of undifferentiated cells in acute leukaemia. British Journal of Haematology 1988, 69:205-211.
23. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). British Journal of Haematology 1991, 78:325-329.
24. Buccheri V, Matutes E, Dyer MJS, et al. Lineage commitment in biphenotypic leukemia. Leukemia 1993, 7:919-927.
25. Matutes E, Morilla R, Farahat N, et al. Definition of acute biphenotypic leukemia. Haematologica 1997, 82:64-66.
26. Brunning RD, Matutes E, Borowitz M, et al. Acute leukaemias of ambiguous lineage. World Health Organization classification of tumours. Tumours of haemopoietic and lymphoid tissues 2001, 27. IARC Press, Lyon. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
27. Feulliard J, Jacob MC, Valensi F, et al. Clinical and biological features of CD4+ CD56+ malignancies. Blood 2002, 99:1556-1563.
28. Chan JKC, Wong KF, Jaffe ES, et al. Aggressive NK cell leukaemia. World Health Organization classification of tumours: tumours of haemopoietic and lymphoid tissues 2001, 198-2000. IARC Press, Lyon. J. ES, H. NL, H. Stein, J.W. Vardiman (Eds.).
29. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994, 8:1640-1645.
30. Zomas AP, Matutes E, Morilla R, et al. Expression of the immunoglobulin associated protein B29 in B-cell disorders with the monoclonal antibody SN8 (CD79b). Leukemia 1996, 10:1966-1970.
31. Moureau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). American Journal of Clinical Pathology 1997, 108:378-382.
32. Cabezudo E, Morilla R, Carrara P, et al. Quantitative analysis of CD79b, CD5 and CD19 in B-cell lymphoproliferative disorders. Haematologica 1999, 84:413-418.
33. Delgado J, Matutes E, Morilla A, et al. Diagnostic significance of CD20 and FMC7 expression in B cell disorders. American Journal of Clinical Pathology 2003, 120:754-759.
34. Matutes E, Morilla R, Owusu-Ankomah K, et al. The immunophenotype of hairy cell leukemia (HCL): proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leukemia and Lymphoma 1994, 14(suppl 1):57-61.
35. del Giudice I, Matutes E, Morilla R, et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004, 89:303-308.
36. De Boer CJ, Schuuring E, Dreef E, et al. Cyclin D1 protein analysis in the diagnosis of mantle-cell lymphoma. Blood 1995, 86:2715-2723.
37. Delmer A, Ajchenbaum-Cymbalista F, Tang R, et al. Overexpression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. British Journal of Haematology 1995, 89:798-804.
38. Elenaei MO, Jadayel DM, Matutes E, et al. Cyclin D1 flow cytometry as a useful tool in the diagnosis of B-cell malignancies. Leukemia Research 2001, 25:115-123.
39. Thornton PD, Gruzka-Westwood AM, Hamoudi RA, et al. Characterisation of TP53 abnormailities in chronic lymphocytic leukaemia. The Hematology Journal 2004, 5:47-54.
40. Lens D, Dyer MJS, Garcia Marco JA, et al. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. British Journal of Haematology 1997, 99:848-857.
41. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995, 85:1580-1589.
42. Damle RN, Walie T, Fais F, et al. Immunoglobulin V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
43. Thornton PD, Fernandez C, Giustolisi G, et al. CD38 as a prognostic indicator in chronic lymphocytic leukaemia. The Hematology Journal 2004, 5:145-151.
44. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for Immunoglobulin variable gene region mutations in chronic lymphocytic leukemia. New England Journal of Medicine 2003, 348:1764-1775.
45. Matutes E Chronic T-cell lymphoproliferative disorders. Reviews in Clinical and Experimental Haematology 2003, 6:401-420.
46. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991, 78:3269-3274.
47. Ginaldi L, Matutes E, Farahat N, et al. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. British Journal of Haematology 1996, 93:921-927.
48. Farahat N, Lens D, Zomas A, et al. Quantitative flow cytometry can distinguish between normal and B-cell precursors. British Journal of Haematology 1995, 91:640-646.
49. Campana D, Counstan-Smith E Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Practice Research on Clinical Haematology 2002, 15:1-19.
50. Cabezudo E, Matutes E, Ramrattan M, et al. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 1997, 11:1909-1914.
51. Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal residual disease levels in chronic lymphocytic leukemia improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29-35.
52. Matutes E, Meeus P, McLennan K, et al. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long term follow-up study. British Journal of Haematology 1997, 98:375-383.